Lung cancer｜司会・講師・ディスカッサントのご紹介

Lung cancer｜Discussion

解説【LBA48】CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small-cell lung cancer (NSCLC)

突田 容子　Tsukita Yoko
（東北大学病院 呼吸器内科 ）

解説【LBA52】Interim Analysis of GALAXIES Lung-201: Phase 2, Randomized, Open-label Platform Study of Belrestotug Plus Dostarlimab in Patients (pts) With Previously Untreated Locally Advanced/Metastatic (LA/M) PD-L1 High (TPS >/=50%) Non-Small Cell Lung Cancer (NSCLC)

土屋 裕子　Tsuchiya Yuko
（北九州市立医療センター 呼吸器内科）

解説【LBA53】Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: results from the randomized phase 2 RELATIVITY-104 study

土屋 裕子　Tsuchiya Yuko
（北九州市立医療センター 呼吸器内科）

解説【LBA55】Mechanisms of Acquired Resistance to First-line Amivantamab Plus Lazertinib Versus Osimertinib in Patients With EGFR-mutant Advanced Non-Small Cell Lung Cancer: An Early Analysis from the Phase 3 MARIPOSA Study

土屋 裕子　Tsuchiya Yuko
（北九州市立医療センター 呼吸器内科）

解説【LBA81】Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial

突田 容子　Tsukita Yoko
（東北大学病院 呼吸器内科 ）

解説【1243MO】A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients (≥75 years) with unresectable locally advanced NSCLC: JCOG1914

突田 容子　Tsukita Yoko
（東北大学病院 呼吸器内科 ）